Abstract
Gastric cancer (GC) progression is frequently characterized by the sustained overexpression of the transcription factor SNAI2, a master regulator of the epithelial-mesenchymal transition (EMT). However, the mechanisms that maintain SNAI2 levels remain poorly understood. This study identifies a "double-negative" feedback loop involving the long non-coding RNA (lncRNA) ELF3-AS1. We show that SNAI2 transcriptionally represses ELF3-AS1, which normally acts to inhibit SNAI2 signaling. Furthermore, ELF3-AS1 physically interacts with ELF3 mRNA to form a duplex that recruits the NF45/NF90 complex, stabilizing the tumor-suppressive ELF3 transcript. The disruption of this regulatory axis drives GC metastasis and correlates with poor patient prognosis, highlighting a novel therapeutic target.
Introduction
Metastasis is the primary cause of mortality in gastric cancer (GC), driven largely by the activation of the epithelial-mesenchymal transition (EMT). SNAI2 (Slug) is a critical transcription factor that orchestrates EMT by repressing epithelial genes and promoting mesenchymal traits. While SNAI2's role in metastasis is well-documented, the regulatory networks that sustain its pathological expression are less clear. Recent evidence suggests that long non-coding RNAs (lncRNAs) play pivotal roles in cancer gene regulation. This study investigates the interplay between SNAI2 and the antisense lncRNA ELF3-AS1 in the context of GC progression.
Methods
The researchers employed a multi-omics approach to map the SNAI2-ELF3-AS1 axis. RNA sequencing (RNA-seq) was used to identify lncRNAs differentially expressed upon SNAI2 modulation. Direct transcriptional repression was validated using Chromatin Immunoprecipitation (ChIP) and dual-luciferase reporter assays. The functional impact of ELF3-AS1 on cell cycle progression and metastasis was evaluated through in vitro assays and in vivo mouse xenograft models. RNA-RNA interactions were characterized using CHIRP and duplex-specific assays, while protein partners were identified via RNA pull-down followed by mass spectrometry. Clinical correlations were derived from TCGA and GSE62254 patient cohorts.
Results
The study identified ELF3-AS1 as a key lncRNA transcriptionally repressed by SNAI2. Clinical analysis revealed that low expression of ELF3-AS1 and its sense gene, ELF3, is significantly associated with poor overall survival in GC patients (p=0.029).
Mechanistically, a "double-negative" feedback loop was discovered: SNAI2 binds to the ELF3-AS1 promoter to inhibit its expression. Conversely, ELF3-AS1 normally suppresses SNAI2 by facilitating the activity of miRNAs (e.g., miR-33a/b, miR-203a) that target SNAI2 mRNA. The loss of ELF3-AS1 thus removes a critical brake on SNAI2, leading to its sustained overexpression and the promotion of metastasis.
Furthermore, ELF3-AS1 was found to regulate the tumor suppressor ELF3 at the post-transcriptional level. ELF3-AS1 forms a physical RNA-RNA duplex with ELF3 mRNA, which serves as a scaffold for the NF45/NF90 (ILF2/ILF3) complex. This interaction stabilizes the ELF3 transcript; in the absence of ELF3-AS1, ELF3 mRNA is rapidly degraded. Functional studies also showed that ELF3-AS1 depletion accelerates the cell cycle by downregulating the checkpoint protein p21 and upregulating CDK6. In mouse models, silencing ELF3-AS1 resulted in larger tumors and increased metastatic spread.
Discussion
These findings reveal a sophisticated regulatory network where a transcription factor (SNAI2) and an antisense lncRNA (ELF3-AS1) mutually regulate each other to control the expression of a tumor suppressor (ELF3). This SNAI2-ELF3-AS1 loop represents a "vicious cycle" that, once activated, drives the aggressive phenotype of gastric cancer. The discovery of the RNA-RNA duplexing mechanism adds a layer of complexity to our understanding of how antisense lncRNAs function, moving beyond simple transcriptional interference to active transcript stabilization.
The clinical correlation between the loss of this axis and poor prognosis suggests that ELF3-AS1 could serve as a valuable biomarker. Therapeutically, targeting this loop—either by inhibiting SNAI2 or restoring ELF3-AS1 function—presents a promising avenue for intervention, though challenges in lncRNA delivery remain.
Conclusion
The SNAI2-ELF3-AS1 feedback loop is a central driver of gastric cancer metastasis. By integrating transcriptional repression and post-transcriptional stabilization, this circuit ensures the persistence of oncogenic signaling. Understanding these multi-layered regulatory mechanisms is essential for developing more effective strategies to combat metastatic gastric cancer.
Summary updated